Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup

[1]  L. Wood,et al.  Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance , 2022, eLife.

[2]  M. Ferracin,et al.  Clinical histopathological features and CDKN2A/CDK4/MITF mutational status of patients with multiple primary melanomas from Bologna: Italy is a fascinating but complex mosaic , 2021, Italian Journal of Dermatology and Venereology.

[3]  S. Puig,et al.  Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia , 2021, Genetics in Medicine.

[4]  F. Couch,et al.  First international workshop of the ATM and cancer risk group (4-5 December 2019) , 2021, Familial Cancer.

[5]  K. Nielsen,et al.  CDKN2A genetic testing in melanoma-prone families in Sweden in the years 2015–2020: implications for novel national recommendations , 2021, Acta oncologica.

[6]  I. Bottillo,et al.  A Single Center Retrospective Review of Patients from Central Italy Tested for Melanoma Predisposition Genes , 2020, International journal of molecular sciences.

[7]  G. Mann,et al.  FRAMe: Familial Risk Assessment of Melanoma—a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma , 2020, Familial cancer.

[8]  A. Ballestrero,et al.  Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1 , 2020, Cancers.

[9]  P. Ghiorzo,et al.  Evolution of approaches to identify melanoma missing heritability , 2020, Expert review of molecular diagnostics.

[10]  C. Massone,et al.  Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients , 2020, Journal of Translational Medicine.

[11]  N. Hayward,et al.  NEK11 as a candidate high-penetrance melanoma susceptibility gene , 2019, Journal of Medical Genetics.

[12]  P. Ascierto,et al.  Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study , 2019, BMC Cancer.

[13]  S. Puig,et al.  Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. , 2019, Journal of the American Academy of Dermatology.

[14]  Ivana K. Kim,et al.  Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide , 2018, Journal of the National Cancer Institute.

[15]  L. Cannon-Albright,et al.  A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma , 2018, Journal of the National Cancer Institute.

[16]  H. Olsson,et al.  CM-Score: a validated scoring system to predict CDKN2A germline mutations in melanoma families from Northern Europe , 2018, Journal of Medical Genetics.

[17]  David J. Adams,et al.  Rare Variant, Gene-Based Association Study of Hereditary Melanoma Using Whole-Exome Sequencing , 2017, Journal of the National Cancer Institute.

[18]  K. Peris,et al.  Characterization of melanoma susceptibility genes in high-risk patients from Central Italy , 2017, Melanoma research.

[19]  P. Queirolo,et al.  Identification, genetic testing, and management of hereditary melanoma , 2017, Cancer and Metastasis Reviews.

[20]  P. Ascierto,et al.  Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. , 2016, Journal of the American Academy of Dermatology.

[21]  Nicholas G. Martin,et al.  POLE mutations in families predisposed to cutaneous melanoma , 2015, Familial Cancer.

[22]  Thomas M. Keane,et al.  Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. , 2015, Journal of the National Cancer Institute.

[23]  X. Hua,et al.  Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma , 2014, Nature Genetics.

[24]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[25]  L. Thomas,et al.  Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants , 2013, Journal of Medical Genetics.

[26]  S. Puig,et al.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma , 2011, Nature.

[27]  S. Tognazzo,et al.  Contribution of susceptibility gene variants to melanoma risk in families from the Veneto region of Italy , 2011, Pigment cell & melanoma research.

[28]  P. Ascierto,et al.  Clinical genetic testing for familial melanoma in Italy: a cooperative study. , 2009, Journal of the American Academy of Dermatology.

[29]  S. Puig,et al.  High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. , 2006, Cancer research.

[30]  A. Goldstein,et al.  Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. , 2006, Human molecular genetics.

[31]  M. Sormani,et al.  Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients , 2004, Melanoma research.

[32]  A. Goldstein,et al.  High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. , 2002, American journal of medical genetics.

[33]  H. Höfler,et al.  CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds. , 1998, The Journal of investigative dermatology.

[34]  C. Garbe,et al.  Epidemiology of Skin Cancer: Update 2019. , 2020, Advances in experimental medicine and biology.

[35]  P. Queirolo,et al.  INK4/ARF germline alterations in pancreatic cancer patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.